San Diego – November 9, 2022 – Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders, and a wholly owned and independently operated subsidiary of Bayer AG, today announced that Jenna Goldberg, M.D., has joined the company as Chief Medical Officer. Dr. Goldberg brings industry leadership experience to Vividion, having held multiple senior medical roles during her career at Janssen Research and Development, a division of Johnson & Johnson.
“Jenna has a broad and successful track record in drug development, having advanced several novel therapies through approval with focus and precision, thereby enabling patients in need to benefit from cancer breakthroughs. Jenna brings proven leadership skills, clinical development expertise and tremendous energy to our growing team,” said Jeffrey Hatfield, chief executive officer of Vividion. “Her addition comes at an exciting inflection point for our growth, as we clearly see the potential to advance multiple programs into the clinic starting next year.”
“I am very excited to join Vividion to continue to advance innovation in an entrepreneurial environment focused on patient benefits and outcomes,” said Dr. Goldberg. “I am impressed by the pipeline’s breadth of novel, first-in-class programs in oncology and immunology. These programs are nearly all targeting proteins the industry has previously viewed as undruggable, and indicate the potential to deliver enormous value to patients if successful. I am also intrigued by the arm’s length business model established with Bayer that allows us to operate largely autonomously and independently but with the technical expertise and financial stability of a major pharmaceutical company.”
Dr. Goldberg has served most recently as Vice President, Early Clinical Development, at Janssen supervising the clinical programs for multiple myeloma, cellular therapy, prostate cancer, as well as clinical pharmacology. Additionally, she served as the Co-Chair of Janssen Oncology Protocol Review Committee, since January 2021. Notably, Dr. Goldberg supervised protocol developments, successful IND submissions of numerous compounds, and all early development clinical efforts for teclistamab, talquetamab, and ciltacabtagene autoleucel, that were either granted breakthrough therapy designation or are currently approved medicines. Dr Goldberg also held other early as well as late development medical roles at Janssen over the past eight years. Prior to joining Janssen, she served as Assistant Attending Physician at Memorial Hospital/Assistant Member of Memorial Sloan-Kettering Cancer Center. Dr. Goldberg holds an M.D. from Johns Hopkins University School of Medicine and an undergraduate from Massachusetts Institute of Technology, with a Bachelor of Science in Biology. Dr. Goldberg did her postdoctoral training as a Fellow at Memorial Sloan Kettering, Cancer Center in Hematology and Oncology as well as a Fellow in Medicine, at Weill Medical College of Cornell University.
